Skip to content

Comparison of Efficacy and Safety between MIRCERA and Roxadustat in the Treatment of Renal Anemia

Comparison of Efficacy and Safety between MIRCERA and Roxadustat in the Treatment of Renal Anemia

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124516
Enrollment
Unknown
Registered
2026-05-13
Start date
2025-06-01
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Maintenance hemodialysis complicated with renal anemia

Interventions

CERA group:None

Sponsors

Guangdong Second Provincial General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Chronic kidney disease dialysis patients, accompanied by renal anemia; 2. Dialysis time lasts at least more than 1 week; 3. Age all >18 years.

Exclusion criteria

Exclusion criteria: 1.Those who received red blood cell transfusion within 8 weeks before enrollment; 2.those with active malignant diseases; 3.tumor patients; 4.those with uncontrolled or chronic immune system diseases; 5.those with complicated severe infections; 6.those with hemolysis or pure red cell aplastic anemia; 7.those with complicated severe cardiac or hepatic dysfunction; 8.pregnant or lactating women, and women of childbearing age who are not using contraception.

Design outcomes

Primary

MeasureTime frame
hemoglobin;

Secondary

MeasureTime frame
blood pressure;

Countries

China

Contacts

Public ContactHaie Tang

Guangdong Second Provincial General Hospital

1964917941@qq.com+86 20 89168219

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026